Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Transplant Complications Drug Development Pipeline Review 2018: Therapeutics Development, Assessment, Companies, Dormant & Discontinued Projects and Product Development Milestones - ResearchAndMarkets.com

Research and Markets
Posted on: 17 Dec 18

The "Transplant Complications Drug Development Pipeline Review, 2018" report has been added to ResearchAndMarkets.com's offering.

Transplant Complications Drug Development Pipeline Review, 2018, provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graft-versus-host disease (GVHD), liver transplant rejection, kidney transplant rejection and lung transplant rejection and features dormant and discontinued products.

GVHD is a complication that can occur after a stem cell or bone marrow transplant and involves the newly transplanted donor cells attacking the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment consists of immunosuppressants. There are 125 products in development for GVHD.

Organ transplantation replaces an injured or diseased organ with a healthy one. Following a transplant, the immune system may consider the transplanted tissue as foreign and work against it. Patients can develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously.

These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses, blocking organ rejection and facilitating a successful transplant. There are 18 products in development for liver transplant rejection, 49 products in development for kidney transplant rejection and 12 products in development for lung transplant rejection.

Molecular targets acted on by products in development for transplantation complications include tyrosine kinases, caspases and chemokine receptors. Companies operating in this pipeline space include Medeor Therapeutics, Amgen and Novartis.

Key Topics Covered:

1 Introduction

2 Therapeutics Development

3 Therapeutics Assessment

4 Companies Involved in Therapeutics Development

5 Dormant Projects

6 Discontinued Products

7 Product Development Milestones

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/4nrkv4/transplant?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005493/en/

Business Wire
www.businesswire.com

Last updated on: 17/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.